Executive Staff

Tom Rose was named executive vice president and chief operations officer on June 21, 2010. He was named chief financial officer for RTI Biologics in February 2008. He also serves as corporate secretary to the board of directors. Rose joined RTI as vice president and CFO in May 2002.

Rose served the previous 10 years as vice president and chief financial officer at A.M. Todd Group, based in Kalamazoo, Mich. Rose earned a bachelor’s degree in business administration from Western Michigan University in Kalamazoo. He has also completed numerous executive education courses at University of Michigan and Northwestern University focusing on strategy and organizational issues.

Roger Rose was named executive vice president and chief commercial officer on June 21, 2010. In February 2008, he was named president of RTI Donor Services, and, in August 2004, he was named executive vice president of RTI. Rose oversees all aspects of the organization’s not-for-profit affiliate, RTI Donor Services, marketing, and the distribution of donated tissue back into the community. He is committed to ensuring a meaningful connection between the donation and transplantation communities.

Rose joined RTI as vice president of donor services in October 2002 and assumed additional responsibility for distribution and marketing in October 2003. Prior to this, Rose spent seven years at Stryker Corporation based in Kalamazoo, Mich., where he held leadership positions in sales and marketing in both the medical and orthopedic divisions.

Rose earned a bachelor’s degree in business administration from Western Michigan University in Kalamazoo and completed numerous executive education courses at UCLA, University of Michigan and Harvard Business School, focusing on finance, leadership, medical marketing, negotiation and strategy.

Carrie Hartill was named executive vice president and chief scientific officer on June 21, 2010. She was named chief scientific officer in March 2007. She joined RTI in November 2001 and was named vice president of quality assurance and regulatory affairs in January 2003. In her role at RTI, Hartill oversees all scientific research, quality assurance, regulatory affairs and clinical studies. She has served as a board member for BioFlorida and is a member of the Advanced Medical Technology Association (AdvaMed). She also serves on the Accreditation Committee and the Strategic Planning Task Force of the American Association of Tissue Banks (AATB). For 18 years prior, she worked in the areas of technology development and market approvals as a freelance consultant working with many major and start-up biotechnology and medical device companies worldwide.

Hartill earned a bachelor’s degree with honors in health sciences from Birmingham University Medical School in England, as well as a master’s degree in management from the University of Wolverhampton in England. Hartill has also earned master’s level credits in sterilization science from Manchester University.

Robert P. Jordheim joined RTI on June 21, 2010 as executive vice president and CFO, and oversees all aspects of finance for the company.

Jordheim has 24 years of progressive corporate finance experience, including 17 years with Medtronic, Inc. Most recently, he served as vice president, finance and business development for Medtronic’s Spinal and Biologics business unit. Previously, he served as vice president, finance for Medtronic’s Surgical Technologies business unit. His tenure with Medtronic also included responsibilities in corporate development and international experience gained through a five-year assignment in Europe. Previous to his tenure at Medtronic, Jordheim served as manager of external reporting at The Fairchild Corporation and an auditor for Deloitte & Touche.

Jordheim earned a bachelor’s degree in business administration from Southern Methodist University and a master’s degree in business administration from the University of Pittsburgh with a concentration in finance.

Robby Lane was named general manager of Tutogen Medical, GmbH in November 2010, after serving as assistant to the chairman and CEO/head of global dental for RTI Biologics from October 2009. He joined RTI in March 2006 as director of marketing and subsequently served as general manager of the company’s spine and orthopedics division and vice president, spine and orthopedics. Previous to RTI, Lane spent five years with DeRoyal Industries as vice president of sales and marketing, and prior to that he served as business manager for hips at Stryker Corporation.

In his role with RTI, Lane oversees development and execution of the comprehensive strategy for our global dental business.

A native of Knoxville, Tenn., Lane earned a bachelor’s degree in zoology from the University of Tennessee. He also earned a master’s degree in business administration from the University of Tennessee.

Dr. Lenny Archibald was named medical director in January 2003. Prior to joining the company, he served the Centers for Disease Control and Prevention (CDC) for seven years, most recently as acting medical director of the Epidemic Information Exchange and medical epidemiologist in the National Center for Infectious Diseases. His investigation on Clostridium-associated infection related to allograft was published in The New England Journal of Medicine in June 2004 and in Clinical Infectious Diseases in July 2005.

Previous to joining the CDC, Dr. Archibald completed infectious disease and microbiology fellowships at Duke University. He received his undergraduate degree from Harvard University, his medical degree from University College Hospital in London, his doctorate from the University of London and completed postgraduate training in internal and tropical medicine in London, Oxford and Liverpool. In October 2003, Dr. Archibald was named a Fellow of the Royal College of Physicians.